(Q26822011)

language of work or name

1 reference

2011

1 reference

1 reference

94

1 reference

issue

3

1 reference

page(s)

177-90

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

cites work

1 reference

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

21 January 2018

1 reference

Molecular pharmacology of somatostatin receptor subtypes

21 January 2018

1 reference

21 January 2018

1 reference

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

21 January 2018

1 reference

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis

21 January 2018

1 reference

Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.

21 January 2018

1 reference

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

21 January 2018

1 reference

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

21 January 2018

1 reference

Expression of peptide receptors in human endocrine tumours of the pancreas

21 January 2018

1 reference

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

21 January 2018

1 reference

Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue

21 January 2018

1 reference

VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome

21 January 2018

1 reference

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

21 January 2018

1 reference

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

21 January 2018

1 reference

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

21 January 2018

1 reference

Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors.

21 January 2018

1 reference

Angiopoietin-2 promotes disease progression of neuroendocrine tumors

21 January 2018

1 reference

The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors

21 January 2018

1 reference

Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors

21 January 2018

1 reference

Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth

21 January 2018

1 reference

KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.

21 January 2018

1 reference

Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

21 January 2018

1 reference

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

21 January 2018

1 reference

Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours

21 January 2018

1 reference

Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells.

21 January 2018

1 reference

Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets

21 January 2018

1 reference

Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells

21 January 2018

1 reference

Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review

21 January 2018

1 reference

Malignant pancreatic endocrine tumor in a child with tuberous sclerosis

21 January 2018

1 reference

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient.

21 January 2018

1 reference

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor

21 January 2018

1 reference

Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells

21 January 2018

1 reference

High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors

21 January 2018

1 reference

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies

21 January 2018

1 reference

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

21 January 2018

1 reference

Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.

21 January 2018

1 reference

Neuroendocrine tumors. Biotherapy

21 January 2018

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?

21 January 2018

1 reference

Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients

21 January 2018

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst 1 receptor

21 January 2018

1 reference

Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists

21 January 2018

1 reference

Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst(3) receptor antagonists

21 January 2018

1 reference

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

21 January 2018

1 reference

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)

21 January 2018

1 reference

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

21 January 2018

1 reference

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

21 January 2018

1 reference

mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours.

21 January 2018

1 reference

Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases.

21 January 2018

1 reference

Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.

21 January 2018

1 reference

Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation

21 January 2018

1 reference

Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors

21 January 2018

1 reference

Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells

21 January 2018

1 reference

Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.

21 January 2018

1 reference

Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors

21 January 2018

1 reference

Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

21 January 2018

1 reference

Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors

21 January 2018

1 reference

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis

21 January 2018

1 reference

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

21 January 2018

1 reference

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists

21 January 2018

1 reference

Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations

21 January 2018

1 reference

7 January 2021

Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas

1 reference

7 January 2021

Incidence rates of exocrine and endocrine pancreatic cancers in the United States

1 reference

7 January 2021

Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors

1 reference

7 January 2021

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

7 January 2021

Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors

1 reference

7 January 2021

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

1 reference

7 January 2021

Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression

1 reference

7 January 2021

MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases

1 reference

7 January 2021

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

1 reference

7 January 2021

Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis

1 reference

7 January 2021

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

1 reference

7 January 2021

Identifiers

1 reference

PubMed publication ID

21893937

1 reference